Fractyl Health (NASDAQ:GUTS) Trading Up 1.1% – Should You Buy?

Fractyl Health, Inc. (NASDAQ:GUTS)’s share price was up 1.1% during mid-day trading on Monday . The stock traded as high as $0.58 and last traded at $0.5755. Approximately 1,343,735 shares changed hands during mid-day trading, a decline of 41% from the average daily volume of 2,265,636 shares. The stock had previously closed at $0.5694.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on GUTS shares. Canaccord Genuity Group restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, March 26th. Morgan Stanley lowered shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $8.00 to $2.00 in a report on Thursday, January 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.40.

Fractyl Health Stock Up 2.7%

The business’s fifty day moving average is $0.47 and its two-hundred day moving average is $1.20. The company has a market cap of $93.68 million, a P/E ratio of -0.32 and a beta of 1.20. The company has a debt-to-equity ratio of 3.23, a quick ratio of 4.78 and a current ratio of 4.78.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.34. Equities analysts predict that Fractyl Health, Inc. will post -0.67 EPS for the current year.

Institutional Investors Weigh In On Fractyl Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new stake in Fractyl Health during the 2nd quarter valued at about $31,000. FNY Investment Advisers LLC bought a new stake in shares of Fractyl Health in the 3rd quarter valued at about $31,000. Scientech Research LLC bought a new stake in shares of Fractyl Health in the 3rd quarter valued at about $49,000. Prelude Capital Management LLC bought a new stake in shares of Fractyl Health in the 3rd quarter valued at about $55,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in shares of Fractyl Health in the 3rd quarter valued at about $56,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.